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Robust optimizationBackground and purpose: The impact of treatment accuracy on NTCP-based patient selection for proton
therapy is currently unknown. This study investigates this impact for oropharyngeal cancer patients.
Materials and methods: Data of 78 patients was used to automatically generate treatment plans for a
simultaneously integrated boost prescribing 70 GyRBE/54.25 GyRBE in 35 fractions. IMRT treatment plans
were generated with three different margins; intensity modulated proton therapy (IMPT) plans for five
different setup and range robustness settings. Four NTCP models were evaluated. Patients were selected
for proton therapy if NTCP reduction was 10% or 5% for grade II or III complications, respectively.
Results: The degree of robustness had little impact on patient selection for tube feeding dependence,
while the margin had. For other complications the impact of the robustness setting was noticeably
higher. For high-precision IMRT (3 mm margin) and high-precision IMPT (3 mm setup/3% range error),
most patients were selected for proton therapy based on problems swallowing solid food (51.3%) fol-
lowed by tube feeding dependence (37.2%), decreased parotid flow (29.5%), and patient-rated xerostomia
(7.7%).
Conclusions: Treatment accuracy has a significant impact on the number of patients selected for proton
therapy. Therefore, it cannot be ignored in estimating the number of patients for proton therapy.
 2017 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 125 (2017) 520–525
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Radiation therapy (RT) combined with chemotherapy is fre-
quently used to treat patients with head and neck cancer. RT is also
associated with acute and late side effects that deteriorate quality
of life (QoL) [1]. Intensity modulated proton therapy (IMPT) is a
promising approach to reduce these adverse effects [2]. However,
costs of IMPT exceed those of photon intensity modulated radia-
tion therapy (IMRT) and world-wide IMPT capacity is limited.
Therefore, IMPT should be applied to patients who are expected
to benefit most.
Langendijk et al. proposed a model-based approach to select
patients for proton therapy based on a reduction in normal tissue
complication probability (DNTCP) calculated from a photon and a
proton treatment plan. If DNTCP exceeds a pre-defined threshold
level, e.g. 10% or 5% for a grade II or grade III complication respec-
tively, IMPT is the treatment of choice [3]. This methodology gives
rise to various concerns. One is that normal-tissue sparing alsodepends on the extra volume irradiated to mitigate errors in
patient setup and proton range [4]. The impact of uncertainties
and the measures to mitigate them, varies for IMRT and IMPT
due to the physical differences between photons and protons. So
while in photon therapy treatment uncertainties are typically com-
pensated using safety margins, in IMPT they are increasingly dealt
with using robust optimization. Recently, van der Voort et al.
derived robustness recipes yielding the setup and range robustness
settings for given distributions of systematic and random setup
errors and systematic range errors [5]. However, the robustness
settings that need to be used depend on the image-guidance proce-
dures that will be applied. In addition, the IMRT margins are sub-
ject to change due to advances in image-guidance procedures.
The aim of this study was to identify the impact of treatment accu-
racy on model-based IMPT patient selection for oropharyngeal can-
cer patients. To this purpose, IMRT and IMPT plans were
automatically generated with various margins and robustness set-
tings and the impact on patient selection was investigated for four
IMRT-derived NTCP models for xerostomia, dysphagia, and tube
feeding.
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Patient group and treatment plan generation
Anonymized CT data and structure sets of 78 consecutive
oropharyngeal patients were used, of whom 24 patients were pre-
viously treated at the Leiden University Medical Center (LUMC)
and 54 patients at the Erasmus MC Cancer Institute. Characteristics
are listed in Table 1. All patients were planned using a simultane-
ously integrated boost scheme prescribing 70 GyRBE to the primary
tumour and pathological lymph nodes (LUMC) or levels with
pathological lymph nodes (Erasmus MC) and 54.25 GyRBE to the
elective nodal areas in 35 fractions. For IMPT, ‘‘minimax” robust
optimization (see section ‘‘Margins and robustness settings”) was
applied to the unmodified clinical target volumes (CTVs). For IMRT
CTVs were expanded to planning target volumes (PTVs). The plan-
ning goal was that 95% of the prescribed dose should be received
by 98% of the PTV (IMRT) or CTV of the worst-case robustness
scenario (IMPT). A constant radiobiological effectiveness (RBE) of
1.0 and 1.1 was assumed for the IMRT and IMPT plans respectively
[6]. All plans were generated using Erasmus-iCycle, an in-house
developed optimizer [7,8]. This optimizer allows to efficiently gen-
erate treatment plans for a large cohort of patients in a fully auto-
mated fashion. Input for this optimizer is a user-defined wish-list,
composed of constraints and prioritized objectives, where each
objective is assigned a certain goal. Based on this wish-list, the
multi-criterial optimizer optimizes the objectives one-by-one
according to the set priorities. In contrast to the objectives, the
constraints have to be met at all times. Separate wish-lists, but
with similar intent, were used for IMRT and IMPT plans (see Sup-
plementary material) [9,10]. Both wish-lists were constructed
based on the same treatment objectives. However, due to the dif-
ferent physical characteristics between photons and protons, the
used wish-lists are not identical. The wish-lists were designed in
close collaboration with radiation oncologists. For the IMRT plans,
we used a 23 equi-angular beam arrangement to simulate volu-
metric arc therapy (VMAT) dose distributions [9]. The dose was
computed in CT-resolution (0.98  0.98  2.5 mm3). For IMPT we
used three equi-angular beams at 60 , 180  and 300 , as sug-
gested by literature [11]. Available proton energies ranged from
69 to 250 MeV with corresponding spot widths ranging from 3.8
to 6.0 mm sigma (in air at the isocentre), respectively. To irradiate
superficially located target regions, we assumed that a range shif-
ter of 57 mm water equivalent thickness could be inserted during
the delivery of a field. Pencil beams were selected and optimized
using the resampling method described by van de Water et al.Table 1
Patient and tumour characteristics.
Characteristics Number %
Sex Male 58 74
Female 20 26
Age <65 47 60
>65 31 40




Bilateral neck irradiation Yes 71 91
No 7 9
Weight loss None 59 75
Moderate 17 22
Severe 2 3
Accelerated radiotherapy Yes 38 49
No 40 51
Radiotherapy plus Cetuximab Yes 14 18
No 64 82
Chemoradiation Yes 22 28
No 56 72[12]. Final dose calculation was performed on a 2  2  2 mm3 grid
and interpolated to CT-resolution. In case of minor violations in
target coverage (<1%) after final dose calculation, the dose distribu-
tion was rescaled to again fulfil the constraint V95%  98%.
CT artefacts were present in 45 patients due to metal dental
artefacts (e.g. fillings). The artefacts may impact IMPT treatment
plan generation and subsequently the NTCP values. Therefore,
IMPT treatment plans were generated before and after artefact
reduction (Metal Deletion Technique v1.1, Revision Radiology) for
five patients with the most severe artefacts.Margins and robustness settings
For IMRT, the CTV was isotropically expanded with a 0, 3, or 5
mm margin to account for geometrical uncertainties with a 5 mm
retraction under the patient’s skin [13]. For IMPT, robust optimiza-
tion was used to account for uncertainties using setup robustness
and range robustness. Nine scenarios were included: setup errors
in the positive and negative direction along three axes (six scenar-
ios), positive and negative range errors (two scenarios) and one
nominal scenario (no errors). Erasmus-iCycle includes these nine
scenarios simultaneously using a ‘‘minimax” optimization
[14,15], and optimizes the worst-case scenario for each objective.
Fractionation is not considered directly, but similar to margins
robustness recipes can be used to determine for fractionated treat-
ments the settings needed to ensure adequate CTV coverage in
patients for given random and systematic error distributions [5].
Setup error scenarios were simulated by laterally shifting the pen-
cil beams. The range error scenarios were generated by altering the
proton energy. Hereto, we transformed the range error into an
equivalent energy adjustment for each spot. The IMRT margins
and IMPT robustness settings are summarized in Table 2. IMRT
plans with 0 mmmargins and IMPT plans with 0 mm setup robust-
ness (SR = 0 mm) and 0% relative range robustness (RR = 0%) were
included for a baseline comparison between IMRT and IMPT.Plan evaluation
All IMRT plans were evaluated for meeting the clinical target
goals (V95%  98%) for the low-dose as well as the high dose PTV
and V107%  2% and V110%  0% for the high dose PTV. For IMPT,
we evaluated the same parameters but then for the CTVs of the
nominal and error scenarios. The dose to organs at risk (OARs)
was checked for outliers and all IMRT and nominal IMPT dose dis-
tributions were evaluated visually.NTCP models
Published NTCP models recently discussed for IMPT patient
selection in the Netherlands were used to compare IMRT and IMPT
plans and assess the impact of margins and robustness settings onTable 2
Used margins and robustness settings for IMRT and IMPT plans. IMPT robustness
settings were first sorted to setup robustness and second to range robustness as setup
robustness has a larger impact on OAR dose than range robustness [9].
IMRT IMPT






Abbreviations: IMRT = intensity modulated radiation therapy; IMPT = intensity
modulated proton therapy; OAR = organ at risk.
522 Proton therapy patient selectionpatient selection. Table 3 lists the four models and their properties
[16–19]. Similarly as in Jakobi et al. [20] the organ receiving the
lowest dose of two paired organs, such as the parotid gland, was
appointed as the contralateral organ. For the model for patient-
rated xerostomia, the baseline xerostomia score (0 = none or 1 = a
bit) was not recorded for our patient group. Therefore we ran-
domly assigned 30% of our patient group with baseline xerosto-
mia = 1 and 70% with baseline xerostomia = 0, which is the ratio
found in the patient training set in the article of Beetz et al. [16].
For the model for decreased parotid flow of Dijkema et al. [17]
the left and right parotid were handled separately when calculat-
ing and comparing NTCP values, meaning we compared the left
parotid glands mutually (DNTCPleft = NTCPleft,IMRT  NTCPleft,IMPT)
and the right parotid glands mutually (DNTCPright = NTCPright,IMRT
 NTCPright,IMPT). The final DNTCP was then the maximum of these,
i.e. max(DNTCPleft, DNTCPright).
For plan comparison the NTCP values of the IMPT plans were
subtracted from those of the IMRT plans, resulting in a DNTCP.
Decision making in favour of IMPT was made when the DNTCP
threshold (10% or 5% for a grade II or grade III complication, respec-
tively) was exceeded. These thresholds had recently been set by
the Dutch Society for Radiation Therapy and Oncology. In addition,
we investigated the impact of the DNTCP threshold on the number
of patients selected for IMPT.Contouring organs at risk
The OARs considered in the NTCP models were the parotid
glands, supraglottic larynx, superior and inferior constrictor mus-
cle (MCS and MCI respectively), and the cricopharyngeal muscle
(MCP). Delineation followed published guidelines [16,21–24]. The
supraglottic larynx was delineated for 17 patients first. Atlas-
based auto-segmentation (Elekta AB, CMS software, version 0.63,
St. Louis) was used to propagate the supraglottic larynx delin-
eations to the remaining patients.Overlap in selection
The NTCP models proposed for IMPT patient selection partially
overlap in type of complication and input parameters (e.g. the
mean dose of OARs). The latter may lead to an overlap in selected
patients between two NTCP models. To determine this overlap we
calculated:




NTCP models used for plan comparison.
NTCP model Grade Endpoint
Wopken et al. [19] III Tube feeding dependence after six mont
Dijkema et al. [17] II <25% Parotid flow for individual parotid
Christianen et al. [18] II Problems swallowing solid food assessed
H&N35 questionnaire
Beetz et al. [16] II Moderate-to-severe patient-rated xerost
assessed by the EORTC QLQ-H&N35 que
Abbreviations: NTCP = normal tissue complication probability; PCM = pharyngeal constriwhere #SelectedPtsModel1 and #SelectedPtsModel2 are the number
of patients selected for IMPT by models 1 and 2, respectively. It
gives the percentage of patients selected by model 2 from the group
of patients already selected by model 1. The overlap was calculated
for a 3 mm margin and a robustness setting of SR = 3 mm/RR = 3%,
assuming high-precision IMRT and IMPT [5,25].
Results
Plan quality
For all IMRT plans, V95% was above 98% for the high-dose and
low-dose PTV and V107% was below 2% and V110% = 0% for the
high-dose PTV. For the IMPT plans, V95% was above 98% for the
high-dose as well as the low-dose CTV error scenarios. The SR =
0 mm/RR = 0% treatment plans of 8 patients had to be rescaled as
the V95% was slightly lower than 98% (range 97.3–97.7%) after
recalculation on the fine dose grid. For 7 treatment plans (4
patients), the V107% in the worst-case error scenario was above
2% (range: 8.0–10.6%) after recalculation on the fine dose grid. As
in the nominal scenario the V107% was below 2% and the V110%
was 0% in all scenarios, those plans were rendered clinically
acceptable.
For the five patients with the most severe CT artefacts the lar-
gest difference in NTCP before and after artefact reduction was
seen for patient-rated xerostomia (average: 0.3%; range: 0.4 to
1.2%). Given these small differences, artefact reduction was not
performed for any of the patients.Patients selected for IMPT per model
The percentage of patients selected for IMPT as a function of
margin and robustness setting is shown in Fig. 1 for each NTCP
model. In general, the percentage of patients selected for IMPT
decreases with increasing robustness setting for a given margin.
Similarly, Fig. 1 shows that for a given robustness setting the per-
centage of patients selected for IMPT decreases with decreasing
margin. Concerning tube feeding dependence and problems swal-
lowing solid food, patients are selected for IMPT even in case of
the hypothetical use of a 0 mm margin compared to nonzero
robustness. The degree of robustness, however, has little impact
on patient selection for tube feeding dependence. For problems
swallowing solid food the impact of the degree of robustness set-
ting is markedly higher as well as for patient-rated xerostomia
for a margin of 5 mm. For a 3 mm margin and robustness setting
of SR = 3 mm/RR = 3%, most patients are selected for IMPT based
on problems swallowing solid food (51.3%), followed by tube feed-
ing dependence (37.2%) and decreased parotid flow (30.8%).Parameters
hs Mean dose of the superior PCM, inferior PCM,






gland after 1 year Mean dose in parotid glands
with the EORTC QLQ- Mean dose superior PCM and supraglottic larynx
Age
omia after six months
stionnaire
Mean dose contralateral parotid gland
Baseline xerostomia score
ctor muscle.
Fig. 1. (a–d) Percentage of patients selected for IMPT (intensity modulated proton therapy) as a function of margins and robustness settings for each of the four models
included in the comparison. A DNTCP (normal tissue complication probability) threshold of 10% for the grade II models and 5% for the grade III model is used. SR = setup
robustness, RR = range robustness.
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mentary materials for absolute NTCP values and their standard
deviations). For the models for tube feeding dependence, decreased
parotid flow, and patient-rated xerostomia, it is noteworthy to
mention that the number of selected patients is relatively stable
if IMRT and IMPT plans with similar accuracy, i.e. with similar mar-
gin and setup robustness, are compared.Overlap in selection
Table 4 shows the overlap between the NTCP models given a 3
mm margin and a robustness setting of SR = 3 mm/RR = 3%. For
tube feeding dependence 29 patients were selected. Of those
patients 55.2% was also selected for decreased parotid flow. Con-
sidering the three models with the highest number of patients
selected, the largest overlap is 66.7% indicating that all three mod-
els contribute for a great portion independently to the number of
patients selected for proton therapy. Also, for the six patients
selected based on patient-rated xerostomia, there is no other
model that selects all these six patients. For high precision IMRT
(3 mm margin) as well as IMPT (SR = 3 mm/RR = 3%) the union of
the percentage of patients selected for IMPT by all four NTCP mod-
els is 77%.Table 4
Overlap between the NTCP models given in percentages. Numbers indicate the percentage
Tube feeding dependence Decreased p
Tube feeding dependence (29) 55.2%
Decreased parotid flow (24) 66.7%
Problems swallowing solid food (40) 42.5% 35.0%
Patient-rated xerostomia (6) 16.7% 16.7%
Abbreviations: NTCP = normal tissue complication probability.Impact of DNTCP threshold
Fig. 2 shows the percentage of patients selected for IMPT as a
function of DNTCP threshold values. The models for patient-rated
xerostomia, problems swallowing solid food and decreased parotid
flow show the same trend. The model for tube feeding dependence
shows the sharpest decrease in patient selection for IMPT at the
lowest DNTCP threshold values. For higher DNTCP thresholds the
majority of patients will be selected for problems swallowing solid
food.Discussion
In this study IMRT as well as IMPT plans were automatically
generated with various margins and robustness settings for 78
patients in order to investigate the impact of treatment accuracy
on patient selection for proton therapy. Based on the results we
conclude that treatment accuracy cannot be ignored in estimating
the number of patients that will be selected for proton therapy.
Improvements in the accuracy of IMPT, IMRT, or both, for example
by implementing improved image guidance techniques can change
patient selection for IMPT. However, if we assume that the
treatment-related accuracy of IMRT and IMPT is equivalent andoverlap of the model in the first column with the model in the first row.





Fig. 2. (a–d) Percentage of patients selected for IMPT (intensity modulated proton therapy) as a function of the NTCP (normal tissue complication probability) threshold for
all four NTCP models. Results are based on IMRT (intensity modulated radiation therapy) plans with a 3 mm margin and IMPT plans with SR = 3 mm/RR = 3%. All 78 patients
were included. SR = setup robustness, RR = range robustness.
524 Proton therapy patient selectionthat similar margins and setup robustness settings result both in
adequate CVT coverage, the number of patients selected is rela-
tively invariant under treatment accuracy. The actual impact of
treatment accuracy on patient selection depends on the parame-
ters included in the models, but none of the four models remained
unaffected. In our study, the degree of setup robustness had a lar-
ger impact on patient selection than range robustness. This is in
agreement with van de Water et al. [10] who showed that the
degree of setup robustness had the biggest impact on NTCP.
Our results showed that the impact of metal dental artefacts on
NTCP is very small and could therefore be ignored in treatment
planning for patient selection. We believe that this can be
explained by the fact that the artefacts are present in only a few
CT slices, while the organs at risk usually extend beyond those
few slices or do not overlap with those slices. We would like to
state that in the deliverable treatment plan the metal dental arte-
facts have to be accounted for.
The generation of a treatment plan usually implies a trade-off
between the coverage of the target volume and sparing of OARs.
For treatment plans that are Pareto optimal [26], dose improve-
ments for a certain OAR will automatically lead to a worsening of
the dose to the target volume or other OARs. In our study, auto-
mated planning was employed using prioritized optimization
based on pre-defined wish-lists to generate Pareto optimal treat-
ment plans. This guarantees the same trade-off between planning
objectives across all patients contributing to consistent results on
the impact of treatment accuracy on proton therapy patient selec-
tion. To what extent wish-lists with alternative prioritizations in
OAR sparing and target coverage or patient-specific prioritizations
may impact patient selection would be interesting to investigate.
Obviously there are inherent differences between treatment
planning for IMRT and IMPT, as IMRT uses PTV margins while
robust optimization was used for IMPT. To that end, it is not
straightforward to compare a specific margin to a specific robust-
ness setting for a fractionated treatment with similar accuracy.
van der Voort et al. derived for the first time robustness recipes
for IMPT [5]. Their results can be used to find for a given treatment
accuracy in a fractioned treatment, the robustness settings thatwould lead to an adequate treatment in a population of head and
neck cancer patients. Still, it would be an interesting topic of future
research to compare IMRT and IMPT treatment plans that are both
generated using robust optimization.
In clinical practice, the Erasmus-iCycle 23-beam IMRT treat-
ment plans are reconstructed automatically in our clinical treat-
ment planning system (Monaco Elekta AB, Stockholm) to
deliverable VMAT plans [9]. The same approach is foreseen for
the IMPT treatment plan. To avoid inducing additional biases
resulting from the reconstruction, we limited patient selection to
the treatment plans generated in Erasmus-iCycle. The final deci-
sion to treat a patient with proton therapy should be based on a
clinically deliverable plan. Therefore, minor differences in patient
selection are expected between the automated approach used in
this study and the final selection based on clinically deliverable
plans.
A limitation of our study was the absence of baseline xerosto-
mia data, which is one of the parameters of the patient-rated
xerostomia model. We randomly assigned baseline xerostomia to
30% of the patients included in this study. To analyse the impact
of this approach, we also analysed the results assuming that all
patients had baseline xerostomia or had no baseline xerostomia.
We found that the baseline score did hardly impact our findings.
Another limitation is that the NTCP models used in this study
were derived from photon treatments, which may result in
reduced accuracy in predicting complications for IMPT. In a recent
study of Blanchard et al., however, it was demonstrated that
photon-based NTCP models were still valid in a cohort of proton-
treated head and neck cancer patients [27]. The impact of the accu-
racy of the NTCP models themselves on the accuracy of IMPT
patient selection is topic of current research.
Fig. 1 shows that for problems swallowing solid food, decreased
parotid flow, and tube feeding dependence the number of patients
selected for IMPT sometimes slightly increased for increasing
robustness. This is most likely a result of the prioritized optimiza-
tion method. An increase in robustness setting may limit the spar-
ing of a highly prioritized OAR. This can give the optimizer more
freedom to decrease the dose in lower prioritized OARs. Depending
T. Arts et al. / Radiotherapy and Oncology 125 (2017) 520–525 525on which OARs benefit and which not, it can result in a decrease in
NTCP for increased robustness setting.
Conclusion
This study shows that treatment accuracy cannot be ignored in
estimating the number of patients selected for proton therapy
based on comparative treatment planning and NTCP evaluations.
It also shows that IMRT and IMPT image-guidance techniques
should be up-to-date, otherwise the patient selection is based on
treatment accuracy and not on the physical properties of the radi-
ation applied.
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